A Bibliometric Review of Cost-Effectiveness Analyses in the Economic and Medical Literature: 1976-2006

Greenberg, Dan; Rosen, Allison B.; Wacht, Oren; Palmer, Jennifer A.; Neumann, Peter J.

doi:10.1177/0272989x09360066

Cited by 23 publications

(24 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,37 Despite these limitations, cost-effectiveness studies are increasing in number and quality. More than 1,400 original cost-effectiveness studies had been published by 2006, 42 and the quality of studies has increased. …”

Section: Challenges In Conducting and Evaluating Economic Analysismentioning

confidence: 99%

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

Anderson¹,

Heidenreich²,

Barnett³

et al. 2014

Circulation

349

126

View full text Add to dashboard Cite

Section: Challenges In Conducting and Evaluating Economic Analysismentioning

confidence: 99%

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

Anderson¹,

Heidenreich²,

Barnett³

et al. 2014

Circulation

349

126

View full text Add to dashboard Cite

“…By 2010, more than 1000 such analyses had been performed [24]. The approach has found acceptance globally and is used regularly in reviewing valuations of technologies by government agencies [109,110] and private payers [25].…”

Section: Genomic Algorithmsmentioning

confidence: 99%

Assigning Value to Medical Algorithms: Implications for Personalized Medicine

Hornberger

2013

Personalized Medicine

View full text Add to dashboard Cite

Genomic algorithms are typically multiple variable, mathematical equations that assign a score or probability to an event of clinical interest. Debate about the valuation of multianalyte algorithm assays highlights the gaps in best practices for valuing technologies. Decisions about valuation are partly about resolving scientific uncertainty, but also involve issues of social norms and political processes. More transparent discussion and understanding of beliefs about the valuation of algorithms would help reduce uncertainty and drive optimal investment in development and adoption of algorithms that improve social welfare; that is, affordably improving population health. Techniques have been evolving for greater public participation and engagement in such deliberations, which are to be encouraged in determining the valuation of genomic algorithms.

show abstract

“…Furthermore, the York Centre for Reviews and Dissemination database has discontinued updates. On the other hand, the Tufts CEA Registry synthesises results, but includes only cost-per-QALY studies and is not completely publicly accessible [16]. …”

Section: Introductionmentioning

confidence: 99%

The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh

Teerawattananon

Tantivess

Yamabhai

et al. 2016

Health Res Policy Sys

Self Cite

View full text Add to dashboard Cite

BackgroundEconomic evaluation has been implemented to inform policy in many areas, including coverage decisions, technology pricing, and the development of clinical practice guidelines. However, there are barriers to evidence-based policy in low- and middle-income countries (LMICs) that include limited stakeholder awareness, resources and data availability, as well as the lack of capacity to conduct country-specific economic evaluations. This study aims to survey health policy experts’ opinions on barriers to use of cost-effectiveness data in these settings and to obtain their advice on how to make a new cost-per-DALY database being developed by Tufts Medical Center more relevant to LMICs. It also identifies the factors influencing transferability.MethodsIn-depth interviews were conducted with 32 participants, including policymakers, technical advisors, and researchers in Health Ministries, universities and non-governmental organisations in Bangladesh, India (New Delhi, Tamil Nadu and Karnataka) and Vietnam.ResultsThe survey revealed that, in all settings, the use of cost-effectiveness information in policy development is lacking, owing to limited knowledge among policymakers and inadequate human resources with health economics expertise in the government sector. Furthermore, researchers in universities do not have close connections with health authorities. In India and Vietnam, the demand for evidence to inform coverage decisions tends to increase as the countries are moving towards universal health coverage. The informants in all countries argue that cost-effectiveness data are useful for decision-makers; however, most of them do not perform data searches by themselves but rely on the information provided by the technical advisor counterparts. Most interviewees were familiar with using evidence from other countries and were also aware of the influences of contextual elements as a limitation of transferability. Finally, strategies to promote the newly developed database include training on basic economic evaluation for policymakers and researchers, and effective communication programs, with support from reputable global agencies.ConclusionsAlthough cost-effectiveness information is recognised as essential in resource allocation, there are several impediments in the generation and use of such evidence to inform priority setting in LMICs. As such, the Cost-per-DALY database should be well-designed and introduced with appropriate promotion strategies so that it will be helpful in real-world policymaking.Electronic supplementary materialThe online version of this article (doi:10.1186/s12961-016-0156-6) contains supplementary material, which is available to authorized users.

show abstract

A Bibliometric Review of Cost-Effectiveness Analyses in the Economic and Medical Literature: 1976-2006

Abstract: The CEA literature continues to proliferate. Coauthorship trends appear to follow the rapid increase in the mean number of authors found in other publication types.

Cited by 23 publications

References 11 publications

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

Assigning Value to Medical Algorithms: Implications for Personalized Medicine

The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh

Contact Info

Product

Resources

About